EUCTR2014-004659-30-Outside-EU/EEA进行中（未招募）不适用
Four-week, open-label, multicenter, randomized, parallel-group study to investigate the pharmacokinetics, safety, tolerability and the effects on leak point pressure of 2 oral doses of alfuzosin (0.1 mg/kg/day; 0.2 mg/kg/day) in children and adolescents 2 to 16 years-of-age with elevated detrusor leak point pressure of neuropathic etiology
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Children and adolescents of either gender 2-16 years of age with elevated detrusor LPP of neuropathic etiology.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 24
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A 4-week, open-label, randomized, multi-centre, parallel-group study evaluating the safety and efficacy of 4 actuations Symbicort (budesonide/formoterol) HFA pMDI 40/2.25ug twice daily, with and without spacer, in children (6-11 years) with asthma - SPACERasthmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2007-002722-29-HUAstraZeneca AB100
已完成
不适用
A single-center, randomized, open-label, four-period, four-treatment, cross-over study to investigate the comparative bioavailability of dispersible tablet and capsule formulations of RO5285119 in healthy volunteers10009841Autism Spectrum DisorderNL-OMON44542F. HoffmannLa Roche Ltd14
进行中（未招募）
1 期
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor AgonistType 2 diabetes mellitusMedDRA version: 19.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-005101-36-SIsanofi-aventis Groupe929
进行中（未招募）
1 期
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor AgonistType 2 diabetes mellitusMedDRA version: 19.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-005101-36-GBsanofi-aventis Groupe929
进行中（未招募）
1 期
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor AgonistType 2 diabetes mellitusMedDRA version: 19.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2015-005101-36-CZsanofi-aventis Groupe1,840